Vertex Pharmaceuticals

NASDAQ: VRTX · Real-Time Price · USD
392.76
2.46 (0.63%)
At close: Aug 15, 2025, 3:59 PM
393.30
0.14%
After-hours: Aug 15, 2025, 07:58 PM EDT

Vertex Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
2.96B 2.77B 2.91B 2.77B 2.65B 2.69B 2.52B 2.48B 2.49B 2.37B 2.3B 2.33B 2.2B 2.1B 2.07B 1.98B 1.79B 1.72B
Cost of Revenue
407.5M 363M 423.4M 392.6M 371.9M 342.6M 368M 318.7M 308.6M 266.9M 283.3M 289.4M 261.8M 245.8M 247.4M 236.51M 227.97M 192.33M
Gross Profit
2.56B 2.41B 2.49B 2.38B 2.27B 2.34B 2.15B 2.16B 2.18B 2.11B 2.02B 2.04B 1.93B 1.85B 1.83B 1.75B 1.57B 1.53B
Operating Income
1.15B 630.1M 1.03B 1.12B -3.51B 1.14B 988.5M 1.04B 1.03B 779M 1.03B 1.13B 1.11B 1.04B 877.7M 1.05B -37.9M 887.83M
Interest Income
122.4M 120.9M 128.2M 132.2M 156.5M 181.2M 179.5M 167.9M 144.7M 122.6M 86M 46.2M 10.8M 1.6M 1.2M 1.12M 1.13M 1.47M
Pretax Income
1.28B 730.4M 1.14B 1.22B -3.39B 1.28B 1.15B 1.18B 1.16B 891.5M 1.08B 1.18B 1.02B 954.8M 870.9M 1.08B -44.2M 820.96M
Net Income
1.03B 646.3M 913M 1.05B -3.59B 1.1B 968.8M 1.04B 915.7M 699.8M 818.9M 930.5M 810.5M 762.1M 770.1M 851.93M 66.92M 653.14M
Selling & General & Admin
424.6M 396.4M 377.6M 371.8M 372.2M 342.7M 369.1M 263.8M 262.6M 241.1M 267.4M 246.8M 215.3M 215.2M 255.2M 198.19M 194.6M 192.08M
Research & Development
978.4M 979.7M 998.7M 875.9M 5.42B 865.9M 1.35B 861.7M 896.2M 742.6M 694.1M 645M 600.1M 603.1M 694.3M 493.75M 1.41B 455.97M
Other Expenses
3.1M 401M 86.3M 15.3M 500K -100K -559.6M n/a 1.6M 345.2M 24.4M 26.4M 12.7M -7.5M n/a n/a 1.6M n/a
Operating Expenses
1.41B 1.78B 1.46B 1.26B 5.79B 1.21B 1.16B 1.13B 1.16B 1.33B 985.9M 918.2M 828.1M 810.8M 949.5M 691.94M 1.6B 648.05M
Interest Expense
3.7M 3M 2.8M 7.5M 9.9M 10.4M 10.6M 10.9M 11.2M 11.4M 11.6M 13.7M 14.6M 14.9M 15.1M 15.26M 15.48M 15.68M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
1.81B 2.14B 1.89B 1.66B 6.16B 1.55B 1.53B 1.45B 1.47B 1.6B 1.27B 1.21B 1.09B 1.06B 1.2B 928.45M 1.83B 840.38M
Income Tax Expense
250.1M 84.1M 223.5M 178.7M 202.4M 179.5M 178.8M 143.9M 245.8M 191.7M 257.9M 245.9M 213.9M 192.7M 100.8M 230.81M -111.18M 167.82M
Shares Outstanding (Basic)
256.7M 256.9M 257.5M 258M 258.1M 258.2M 257.7M 258M 257.7M 257.4M 256.9M 256.5M 255.9M 255.1M 254.6M 257.88M 258.99M 259.37M
Shares Outstanding (Diluted)
258.9M 259.5M 260.5M 261M 258.1M 261.1M 260.9M 260.6M 260.4M 260.3M 260.3M 259.5M 258.7M 257.9M 257M 259.71M 261.02M 261.92M
EPS (Basic)
4.02 2.52 3.55 4.05 -13.92 4.26 3.76 4.01 3.55 2.72 3.19 3.63 3.17 2.99 3.02 3.30 0.26 2.52
EPS (Diluted)
3.99 2.49 3.50 4.01 -13.92 4.21 3.71 3.97 3.52 2.69 3.15 3.59 3.13 2.96 3.00 3.28 0.26 2.49
EBITDA
1.42B 781.8M 1.18B 1.28B -3.33B 1.34B 1.22B 1.23B 1.21B 941.7M 1.13B 1.23B 1.08B 1.01B 919.83M 1.13B 2.6M 865.47M
EBIT
1.29B 733.4M 1.14B 1.23B -3.38B 1.29B 1.16B 1.19B 1.17B 902.9M 1.09B 1.19B 1.04B 969.7M 886.04M 1.1B -28.7M 836.64M
Depreciation & Amortization
135.6M 48.4M 46.5M 53.2M 54M 53.5M 59M 42.1M 41.4M 38.8M 38.4M 36.7M 37.3M 35.9M 33.83M 31.7M 31.3M 28.83M